Soon Sun Kim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5679863/publications.pdf Version: 2024-02-01



SOON SUN KIM

#	Article	IF	CITATIONS
1	Serum Exosomal MicroRNA, miR-10b-5p, as a Potential Diagnostic Biomarker for Early-Stage Hepatocellular Carcinoma. Journal of Clinical Medicine, 2020, 9, 281.	2.4	83
2	Circulating Microbiota-Based Metagenomic Signature for Detection of Hepatocellular Carcinoma. Scientific Reports, 2019, 9, 7536.	3.3	51
3	Nonalcoholic fatty liver disease as a sentinel marker for the development of diabetes mellitus in non-obese subjects. Digestive and Liver Disease, 2018, 50, 370-377.	0.9	45
4	Serum small extracellular vesicleâ€derived <i>LINC00853</i> as a novel diagnostic marker for early hepatocellular carcinoma. Molecular Oncology, 2020, 14, 2646-2659.	4.6	45
5	Endoscopic ultrasound-guided sampling of solid pancreatic masses: 22-gauge aspiration versus 25-gauge biopsy needles. BMC Gastroenterology, 2015, 15, 122.	2.0	40
6	Improvement of Nonalcoholic Fatty Liver Disease Reduces the Risk of Type 2 Diabetes Mellitus. Gut and Liver, 2019, 13, 440-449.	2.9	40
7	Liver stiffness measured by MR elastography is a predictor of early HCC recurrence after treatment. European Radiology, 2020, 30, 4182-4192.	4.5	35
8	Plasma micoRNAâ€122 as a predictive marker for treatment response following transarterial chemoembolization in patients with hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 199-207.	2.8	23
9	Early detection of hepatocellular carcinoma via liquid biopsy: panel of small extracellular vesicleâ€derived long noncoding RNAs identified as markers. Molecular Oncology, 2021, 15, 2715-2731.	4.6	22
10	Microbiome as a potential diagnostic and predictive biomarker in severe alcoholic hepatitis. Alimentary Pharmacology and Therapeutics, 2021, 53, 540-551.	3.7	22
11	Clinical outcomes of transjugular intrahepatic portosystemic shunt for portal hypertension: Korean multicenter real-practice data. Clinical and Molecular Hepatology, 2014, 20, 18.	8.9	22
12	Wire-guided cannulation over a pancreatic stent versus double guidewire technique in patients with difficult biliary cannulation. BMC Gastroenterology, 2015, 15, 150.	2.0	20
13	Plasma MicroRNA-21, 26a, and 29a-3p as Predictive Markers for Treatment Response Following Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. Journal of Korean Medical Science, 2018, 33, e6.	2.5	18
14	Interleukin-8 level as a prognostic marker in patients with hepatitis B virus-associated hepatocellular carcinoma treated with transarterial chemoembolization. Cytokine, 2015, 76, 449-457.	3.2	16
15	Non-neoplastic pathology results after endoscopic submucosal dissection for gastric epithelial dysplasia or early gastric cancer. Endoscopy, 2015, 47, 598-604.	1.8	16
16	Prediction of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis Using 4-Hour Post-Endoscopic Retrograde Cholangiopancreatography Serum Amylase and Lipase Levels. Journal of Korean Medical Science, 2017, 32, 1814.	2.5	15
17	Analysis of endoscopic features for histologic discrepancies between biopsy and endoscopic submucosal dissection in gastric neoplasms: 10-year results. Digestive and Liver Disease, 2019, 51, 79-85.	0.9	15
18	Liver stiffness in magnetic resonance elastography is prognostic for sorafenib-treated advanced hepatocellular carcinoma. European Radiology, 2021, 31, 2507-2517.	4.5	9

SOON SUN KIM

#	Article	IF	CITATIONS
19	Novel Gene Signatures as Prognostic Biomarkers for Predicting the Recurrence of Hepatocellular Carcinoma. Cancers, 2022, 14, 865.	3.7	9
20	Pathway-Based Integrative Analysis of Metabolome and Microbiome Data from Hepatocellular Carcinoma and Liver Cirrhosis Patients. Cancers, 2020, 12, 2705.	3.7	7
21	Predictive score for hepatocellular carcinoma after hepatitis B e antigen loss in patients treated with entecavir or tenofovir. Journal of Viral Hepatitis, 2020, 27, 1052-1060.	2.0	7
22	Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C. Gut and Liver, 2021, 15, 410-419.	2.9	7
23	Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma. Yonsei Medical Journal, 2021, 62, 12.	2.2	6
24	<i>HMBS</i> is the most suitable reference gene for RT‑qPCR in human HCC tissues and blood samples. Oncology Letters, 2021, 22, 791.	1.8	6
25	Hypomethylation-mediated upregulation of the WASF2 promoter region correlates with poor clinical outcomes in hepatocellular carcinoma. Journal of Experimental and Clinical Cancer Research, 2022, 41, 158.	8.6	6
26	Risk Prediction Model Based on Magnetic Resonance Elastography-Assessed Liver Stiffness for Predicting Posthepatectomy Liver Failure in Patients with Hepatocellular Carcinoma. Gut and Liver, 2022, 16, 277-289.	2.9	5
27	Relationship between the dynamics of non-alcoholic fatty liver disease and incident diabetes mellitus. Scientific Reports, 2022, 12, 2538.	3.3	3
28	Effect of direct-acting antivirals for hepatitis C virus-related hepatocellular carcinoma recurrence and death after curative treatment. Journal of Liver Cancer, 2022, 22, 125-135.	1.1	3
29	Diagnostic Yield of Transabdominal Ultrasonography for Evaluation of Pancreatic Cystic Lesions Compared with Endoscopic Ultrasonography. Journal of Clinical Medicine, 2021, 10, 4616.	2.4	2
30	Infiltrative hepatocellular carcinoma with multiple lung metastasis completely cured using nivolumab: a case report. Journal of Liver Cancer, 2021, 21, 169-176.	1.1	1
31	Cyclic Change of Sphincter of Oddi Motility and Its Relationship with Small Bowel Migrating Motor Complex in Humans. Digestive Diseases and Sciences, 2018, 63, 3425-3433.	2.3	0
32	Outcomes and Loop Pattern Analysis of a Road-Map Technique for ERCP with Side-Viewing Duodenoscope in Patients with Billroth II Gastrectomy (with Video). Journal of Personalized Medicine, 2021, 11, 404.	2.5	0